Association of Obesity based on Different Metabolic Status with Risk of Gout Occurrence in Patients: A National Study.

IF 2 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Endocrine, metabolic & immune disorders drug targets Pub Date : 2024-01-01 DOI:10.2174/1871530323666230911140635

Yanyan Wang, Luna Liu, Shizhan Ma, Junming Han, Zhixiang Wang, Xiude Fan, Xu Hou

{"title":"Association of Obesity based on Different Metabolic Status with Risk of Gout Occurrence in Patients: A National Study.","authors":"Yanyan Wang, Luna Liu, Shizhan Ma, Junming Han, Zhixiang Wang, Xiude Fan, Xu Hou","doi":"10.2174/1871530323666230911140635","DOIUrl":null,"url":null,"abstract":"Background: Obesity often co-exists with metabolic abnormalities, but the results of studies on the relationship between obesity, metabolic abnormalities and the risk of gout are inconsistent.Objectives: We aimed to study whether there was a mutual regulation between obesity, metabolic abnormalities and the risk of gout.Methods: We conducted a cross-sectional study to expound the association between obesity based on different metabolic statuses and the risk of gout. Patients were derived from Nationwide Readmission Database (2018 sample).Results: A total of 9,668,330 records were recruited for analysis from January to December. The risk of gout in the obesity group, metabolic abnormalities group and obesity combined with metabolic abnormalities group was 1.67 times (OR = 1.67, 95%CI 1.64-1.70), 3.12 times (OR = 3.12, 95%CI 3.09-3.15) and 4.27 times (OR = 4.27, 95%CI 4.22-4.32) higher than that in the normal control group. For different metabolic components, OR value was highest in hypertension group (OR = 2.65, 95%CI 2.60-2.70 and OR = 4.85, 95%CI 4.73-4.97), followed by dyslipidemia group (OR = 2.23, 95%CI 2.16-2.30 and OR = 3.74, 95%CI 3.55-3.95) and in hyperglycemia group (OR = 1.73, 95%CI 1.66-1.80 and OR = 2.94, 95%CI 2.78-3.11). Fewer components of metabolic syndrome were associated with a lower risk of gout in both nonobese and obese patients.Conclusion: When metabolic abnormalities were present, obesity induced a higher risk of gout. Different components of metabolic abnormalities had different effects on the risk of gout occurrence, and the number of metabolic abnormalities was closely related to the risk of gout occurrence. Follow-up and intervention methods targeting obesity and metabolic abnormalities should be considered for patients with gout.","PeriodicalId":11614,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":"973-980"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871530323666230911140635","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Obesity often co-exists with metabolic abnormalities, but the results of studies on the relationship between obesity, metabolic abnormalities and the risk of gout are inconsistent.

Objectives: We aimed to study whether there was a mutual regulation between obesity, metabolic abnormalities and the risk of gout.

Methods: We conducted a cross-sectional study to expound the association between obesity based on different metabolic statuses and the risk of gout. Patients were derived from Nationwide Readmission Database (2018 sample).

Results: A total of 9,668,330 records were recruited for analysis from January to December. The risk of gout in the obesity group, metabolic abnormalities group and obesity combined with metabolic abnormalities group was 1.67 times (OR = 1.67, 95%CI 1.64-1.70), 3.12 times (OR = 3.12, 95%CI 3.09-3.15) and 4.27 times (OR = 4.27, 95%CI 4.22-4.32) higher than that in the normal control group. For different metabolic components, OR value was highest in hypertension group (OR = 2.65, 95%CI 2.60-2.70 and OR = 4.85, 95%CI 4.73-4.97), followed by dyslipidemia group (OR = 2.23, 95%CI 2.16-2.30 and OR = 3.74, 95%CI 3.55-3.95) and in hyperglycemia group (OR = 1.73, 95%CI 1.66-1.80 and OR = 2.94, 95%CI 2.78-3.11). Fewer components of metabolic syndrome were associated with a lower risk of gout in both nonobese and obese patients.

Conclusion: When metabolic abnormalities were present, obesity induced a higher risk of gout. Different components of metabolic abnormalities had different effects on the risk of gout occurrence, and the number of metabolic abnormalities was closely related to the risk of gout occurrence. Follow-up and intervention methods targeting obesity and metabolic abnormalities should be considered for patients with gout.

查看原文本刊更多论文

基于不同代谢状态的肥胖与痛风患者发病风险的关系：一项全国性研究。

背景：肥胖往往与代谢异常同时存在，但有关肥胖、代谢异常和痛风风险之间关系的研究结果并不一致：我们的目的是研究肥胖、代谢异常和痛风风险之间是否存在相互制约的关系：我们进行了一项横断面研究，以阐述不同代谢状态下的肥胖与痛风风险之间的关系。患者来源于全国再住院数据库（2018年样本）：从1月至12月，共收集了9668330条记录进行分析。肥胖组、代谢异常组和肥胖合并代谢异常组的痛风风险分别是正常对照组的1.67倍（OR = 1.67，95%CI 1.64-1.70）、3.12倍（OR = 3.12，95%CI 3.09-3.15）和4.27倍（OR = 4.27，95%CI 4.22-4.32）。就不同的代谢成分而言，高血压组的 OR 值最高（OR = 2.65，95%CI 2.60-2.70 和 OR = 4.85，95%CI 4.73-4.97），其次是血脂异常组（OR = 2.23，95%CI 2.16-2.30 和 OR = 3.74，95%CI 3.55-3.95）和高血糖组（OR = 1.73，95%CI 1.66-1.80 和 OR = 2.94，95%CI 2.78-3.11）。在非肥胖和肥胖患者中，代谢综合征的成分越少，患痛风的风险越低：结论：当存在代谢异常时，肥胖诱发痛风的风险较高。结论：当存在代谢异常时，肥胖会诱发更高的痛风风险。代谢异常的不同成分对痛风发生风险的影响不同，代谢异常的数量与痛风发生风险密切相关。痛风患者应考虑采取针对肥胖和代谢异常的随访和干预方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine, metabolic & immune disorders drug targets ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY

CiteScore

4.60

自引率

5.30%

发文量

217

期刊介绍： Aims & Scope This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.